Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 19/20 | 0.68 |
| ▸ | SLC5A1 | P13866 | 11/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.63 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1037836 | 1.00 | SLC5A2 (0.68) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2997996 | 1.00 | SLC5A2 (0.68) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1036867 | 1.00 | SLC5A2 (0.68) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL16473307 | 0.88 | SLC5A2 (0.64) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14188980 | 0.85 | SLC5A2 (0.60) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1487476 | 0.81 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1039664 | 0.80 | SLC5A2 (0.59) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL16457244 | 0.80 | SLC5A2 (0.59) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL16457243 | 0.80 | SLC5A2 (0.59) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL48097 | 0.79 | SLC5A2 (0.67) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218650-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | LEXICON PHARMACEUTICALS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20210038626-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2021-02-11 | — | — | US | disclosed |
| US-20180311266-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | LEXICON PHARMACEUTICALS, INC. | 2018-11-01 | — | — | US | disclosed |
| EP-2542236-B1 | COMBINATIONS COMPRISING 6-BENZYLPHENYL-2- SULFURTERAHYDROPYRAN-3,4,5-TRIOL DERIVATIVES AS INHIBITORS OF SODIUM -GLUCOSE COTRANSPORTERS 1 AND 2 FOR USE IN DIABETIC PATIENTS | LEXICON PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160296547-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | CHEN JINLING (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160022718-A1 | METHODS OF LOWERING BLOOD PRESSURE | LEXICON PHARMACEUTICALS INC (US) | 2016-01-28 | — | — | US | disclosed |
| US-20150111840-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | CHEN JINLING (US) | 2015-04-23 | — | — | US | disclosed |
| EP-2308841-B1 | Phlorizin analogs as SGLT2 inhibitors | LEXICON PHARMACEUTICALS INC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20140018308-A1 | METHODS OF LOWERING BLOOD PRESSURE | LEXICON PHARMACEUTICALS INC (US) | 2014-01-16 | — | — | US | disclosed |
| US-20120172320-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | PATHEON INC. (CA) | 2012-07-05 | — | — | US | disclosed |
| US-20110218159-A1 | METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | LEXICON PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | disclosed |
| EP-2308841-A2 | Phlorizin analogs as SGLT2 inhibitors | Lexicon Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-2089361-B1 | INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2011-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111840-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 557/4885 |
| US-20180311266-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 557/4885 |
| US-20120172320-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 557/4885 |
| US-20160022718-A1 | METHODS OF LOWERING BLOOD PRESSURE | APOB, SLC5A2, HMGCR | SLC5A2 2/4885SLC5A1 7/4885ADRA2A 122/4885 |
| US-20140018308-A1 | METHODS OF LOWERING BLOOD PRESSURE | APOB, SLC5A2, HMGCR | SLC5A2 2/4885SLC5A1 7/4885ADRA2A 122/4885 |
| US-20160296547-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 557/4885 |
| US-20210038626-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 557/4885 |
| US-20110218159-A1 | METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 457/4885 |
| US-20230218650-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.